Spark Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Spark Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,700	Closed	-$1.9M	–	778
2018 Q3	$1.9M	Sell	4,700 -8,800	-65%	-$3.35M	0.11%	264
2018 Q2	$4.66M	Buy	+13,500	New	+$4.22M	0.27%	118
2016 Q4	–	Sell	-3,900	Closed	-$1.57M	–	855
2016 Q3	$1.57M	Hold	3,900	–	–	0.13%	238
2016 Q2	$1.36M	Buy	+3,900	New	+$1.5M	0.13%	257

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Spark Investment Management's REGN Position: Q4 2018 in Review

Spark Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 4,700 shares — an estimated $1.9M sold.

Spark Investment Management first reported a position in REGN in Q2 2016 and held it in 4 quarters. The position peaked at $4.66M in Q2 2018. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Spark Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Spark Investment Management sold 4,700 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $1.9M.
Spark Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 4 quarters.
Spark Investment Management's Regeneron Pharmaceuticals position peaked at $4.66M in Q2 2018.
670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Spark Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.